Table 1 Progression for 2560 AREDS AMD (Category 1–3 at Baseline) patients over 10.3 years (Yu et al. [4])
From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
AMD category | n | Progressed to next stage | No progression |
|---|---|---|---|
1 | 713 | 494 (69Â %) | 219 (31Â %) |
2 | 1190 | 376 (32Â %) | 814 (68Â %) |
3 | 1527 | 578 (8Â %) | 949 (62Â %) |
3–4 | 280 | 280 (18 %) | NA |
3–5 | 298 | 298 (20 %) | NA |